BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sookoian S, Salatino A, Castaño GO, Landa MS, Fijalkowky C, Garaycoechea M, Pirola CJ. Intrahepatic bacterial metataxonomic signature in non-alcoholic fatty liver disease. Gut 2020;69:1483-91. [PMID: 31900291 DOI: 10.1136/gutjnl-2019-318811] [Cited by in Crossref: 54] [Cited by in F6Publishing: 46] [Article Influence: 27.0] [Reference Citation Analysis]
Number Citing Articles
1 Tilg H, Burcelin R, Tremaroli V. Liver tissue microbiome in NAFLD: next step in understanding the gut-liver axis? Gut 2020;69:1373-4. [PMID: 32060128 DOI: 10.1136/gutjnl-2019-320490] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
2 Luci C, Bourinet M, Leclère PS, Anty R, Gual P. Chronic Inflammation in Non-Alcoholic Steatohepatitis: Molecular Mechanisms and Therapeutic Strategies. Front Endocrinol (Lausanne) 2020;11:597648. [PMID: 33384662 DOI: 10.3389/fendo.2020.597648] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
3 Massier L, Blüher M, Kovacs P, Chakaroun RM. Impaired Intestinal Barrier and Tissue Bacteria: Pathomechanisms for Metabolic Diseases. Front Endocrinol (Lausanne) 2021;12:616506. [PMID: 33767669 DOI: 10.3389/fendo.2021.616506] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
4 Luo Z, Ji Y, Gao H, Gomes Dos Reis FC, Bandyopadhyay G, Jin Z, Ly C, Chang YJ, Zhang D, Kumar D, Ying W. CRIg+ Macrophages Prevent Gut Microbial DNA-Containing Extracellular Vesicle-Induced Tissue Inflammation and Insulin Resistance. Gastroenterology 2021;160:863-74. [PMID: 33152356 DOI: 10.1053/j.gastro.2020.10.042] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
5 Herrema H, Niess JH. Intestinal microbial metabolites in human metabolism and type 2 diabetes. Diabetologia 2020;63:2533-47. [PMID: 32880688 DOI: 10.1007/s00125-020-05268-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
6 Suppli MP, Bagger JI, Lelouvier B, Broha A, Demant M, Kønig MJ, Strandberg C, Lund A, Vilsbøll T, Knop FK. Hepatic microbiome in healthy lean and obese humans. JHEP Rep 2021;3:100299. [PMID: 34169247 DOI: 10.1016/j.jhepr.2021.100299] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 8.0] [Reference Citation Analysis]
7 Hong Y, Li B, Zheng N, Wu G, Ma J, Tao X, Chen L, Zhong J, Sheng L, Li H. Integrated Metagenomic and Metabolomic Analyses of the Effect of Astragalus Polysaccharides on Alleviating High-Fat Diet-Induced Metabolic Disorders. Front Pharmacol 2020;11:833. [PMID: 32587515 DOI: 10.3389/fphar.2020.00833] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
8 Lim JJ, Dutta M, Dempsey JL, Lehmler HJ, MacDonald J, Bammler T, Walker C, Kavanagh TJ, Gu H, Mani S, Cui JY. Neonatal Exposure to BPA, BDE-99, and PCB Produces Persistent Changes in Hepatic Transcriptome Associated With Gut Dysbiosis in Adult Mouse Livers. Toxicol Sci 2021;184:83-103. [PMID: 34453844 DOI: 10.1093/toxsci/kfab104] [Reference Citation Analysis]
9 Tilg H, Adolph TE, Dudek M, Knolle P. Non-alcoholic fatty liver disease: the interplay between metabolism, microbes and immunity. Nat Metab 2021;3:1596-607. [DOI: 10.1038/s42255-021-00501-9] [Reference Citation Analysis]
10 Tilg H, Adolph TE, Moschen AR. Multiple Parallel Hits Hypothesis in Nonalcoholic Fatty Liver Disease: Revisited After a Decade. Hepatology 2021;73:833-42. [PMID: 32780879 DOI: 10.1002/hep.31518] [Cited by in Crossref: 74] [Cited by in F6Publishing: 62] [Article Influence: 74.0] [Reference Citation Analysis]
11 Hullar MAJ, Jenkins IC, Randolph TW, Curtis KR, Monroe KR, Ernst T, Shepherd JA, Stram DO, Cheng I, Kristal BS, Wilkens LR, Franke A, Le Marchand L, Lim U, Lampe JW. Associations of the gut microbiome with hepatic adiposity in the Multiethnic Cohort Adiposity Phenotype Study. Gut Microbes 2021;13:1965463. [PMID: 34491886 DOI: 10.1080/19490976.2021.1965463] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
12 Zhao M, Chen S, Ji X, Shen X, You J, Liang X, Yin H, Zhao L. Current innovations in nutraceuticals and functional foods for intervention of non-alcoholic fatty liver disease. Pharmacol Res 2021;166:105517. [PMID: 33636349 DOI: 10.1016/j.phrs.2021.105517] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Wang T, Ishikawa T, Sasaki M, Chiba T. Oral and Gut Microbial Dysbiosis and Non-alcoholic Fatty Liver Disease: The Central Role of Porphyromonas gingivalis. Front Med (Lausanne) 2022;9:822190. [PMID: 35308549 DOI: 10.3389/fmed.2022.822190] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
14 Kong Y, Yan T, Tong Y, Deng H, Tan C, Wan M, Wang M, Meng X, Wang Y. Gut Microbiota Modulation by Polyphenols from Aronia melanocarpa of LPS-Induced Liver Diseases in Rats. J Agric Food Chem 2021;69:3312-25. [PMID: 33688735 DOI: 10.1021/acs.jafc.0c06815] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
15 Pirola CJ, Salatino A, Quintanilla MF, Castaño GO, Garaycoechea M, Sookoian S. The influence of host genetics on liver microbiome composition in patients with NAFLD. EBioMedicine 2022;76:103858. [PMID: 35092912 DOI: 10.1016/j.ebiom.2022.103858] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Chen J, Ding X, Wu R, Tong B, Zhao L, Lv H, Meng X, Liu Y, Ren B, Li J, Jian T, Li W. Novel Sesquiterpene Glycoside from Loquat Leaf Alleviates Type 2 Diabetes Mellitus Combined with Nonalcoholic Fatty Liver Disease by Improving Insulin Resistance, Oxidative Stress, Inflammation, and Gut Microbiota Composition. J Agric Food Chem 2021;69:14176-91. [PMID: 34783554 DOI: 10.1021/acs.jafc.1c05596] [Reference Citation Analysis]
17 Burz SD, Monnoye M, Philippe C, Farin W, Ratziu V, Strozzi F, Paillarse JM, Chêne L, Blottière HM, Gérard P. Fecal Microbiota Transplant from Human to Mice Gives Insights into the Role of the Gut Microbiota in Non-Alcoholic Fatty Liver Disease (NAFLD). Microorganisms 2021;9:199. [PMID: 33477939 DOI: 10.3390/microorganisms9010199] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
18 Martínez-Montoro JI, Kuchay MS, Balaguer-Román A, Martínez-Sánchez MA, Frutos MD, Fernández-García JC, Ramos-Molina B. Gut microbiota and related metabolites in the pathogenesis of nonalcoholic steatohepatitis and its resolution after bariatric surgery. Obes Rev 2021;:e13367. [PMID: 34729904 DOI: 10.1111/obr.13367] [Reference Citation Analysis]
19 Schneider KM, Elfers C, Ghallab A, Schneider CV, Galvez EJC, Mohs A, Gui W, Candels LS, Wirtz TH, Zuehlke S, Spiteller M, Myllys M, Roulet A, Ouzerdine A, Lelouvier B, Kilic K, Liao L, Nier A, Latz E, Bergheim I, Thaiss CA, Hengstler JG, Strowig T, Trautwein C. Intestinal Dysbiosis Amplifies Acetaminophen-Induced Acute Liver Injury. Cell Mol Gastroenterol Hepatol 2021;11:909-33. [PMID: 33189892 DOI: 10.1016/j.jcmgh.2020.11.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
20 Bajaj JS, Khoruts A. Microbiota changes and intestinal microbiota transplantation in liver diseases and cirrhosis. Journal of Hepatology 2020;72:1003-27. [DOI: 10.1016/j.jhep.2020.01.017] [Cited by in Crossref: 34] [Cited by in F6Publishing: 37] [Article Influence: 17.0] [Reference Citation Analysis]
21 Cai J, Zhang XJ, Ji YX, Zhang P, She ZG, Li H. Nonalcoholic Fatty Liver Disease Pandemic Fuels the Upsurge in Cardiovascular Diseases. Circ Res 2020;126:679-704. [PMID: 32105577 DOI: 10.1161/CIRCRESAHA.119.316337] [Cited by in Crossref: 30] [Cited by in F6Publishing: 12] [Article Influence: 15.0] [Reference Citation Analysis]
22 Shepard CR. TLR9 in MAFLD and NASH: At the Intersection of Inflammation and Metabolism. Front Endocrinol (Lausanne) 2020;11:613639. [PMID: 33584545 DOI: 10.3389/fendo.2020.613639] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
23 Hoozemans J, de Brauw M, Nieuwdorp M, Gerdes V. Gut Microbiome and Metabolites in Patients with NAFLD and after Bariatric Surgery: A Comprehensive Review. Metabolites 2021;11:353. [PMID: 34072995 DOI: 10.3390/metabo11060353] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Tilg H, Adolph TE. Liver microbes controlling immunity: Facts and pitfalls. Cell Metab 2022;34:510-2. [PMID: 35385703 DOI: 10.1016/j.cmet.2022.03.001] [Reference Citation Analysis]
25 Targher G, Tilg H, Byrne CD. Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach. Lancet Gastroenterol Hepatol 2021;6:578-88. [PMID: 33961787 DOI: 10.1016/S2468-1253(21)00020-0] [Cited by in Crossref: 51] [Cited by in F6Publishing: 36] [Article Influence: 51.0] [Reference Citation Analysis]
26 Giraud J, Saleh M. Host-Microbiota Interactions in Liver Inflammation and Cancer. Cancers (Basel) 2021;13:4342. [PMID: 34503151 DOI: 10.3390/cancers13174342] [Reference Citation Analysis]
27 Sun D, Zuo C, Huang W, Wang J, Zhang Z. Triclosan targeting of gut microbiome ameliorates hepatic steatosis in high fat diet-fed mice. J Antibiot (Tokyo) 2022. [PMID: 35440769 DOI: 10.1038/s41429-022-00522-w] [Reference Citation Analysis]
28 Li C, Yu S, Li X, Cao Y, Li M, Ji G, Zhang L. Medicinal Formula Huazhi-Rougan Attenuates Non-Alcoholic Steatohepatitis Through Enhancing Fecal Bile Acid Excretion in Mice. Front Pharmacol 2022;13:833414. [PMID: 35721143 DOI: 10.3389/fphar.2022.833414] [Reference Citation Analysis]
29 Hyun H, Lee MS, Park I, Ko HS, Yun S, Jang DH, Kim S, Kim H, Kang JH, Lee JH, Kwon T. Analysis of Porcine Model of Fecal-Induced Peritonitis Reveals the Tropism of Blood Microbiome. Front Cell Infect Microbiol 2021;11:676650. [PMID: 34527598 DOI: 10.3389/fcimb.2021.676650] [Reference Citation Analysis]
30 Liakina V, Strainiene S, Stundiene I, Maksimaityte V, Kazenaite E. Gut microbiota contribution to hepatocellular carcinoma manifestation in non-alcoholic steatohepatitis. World J Hepatol 2022; 14(7): 1277-1290 [DOI: 10.4254/wjh.v14.i7.1277] [Reference Citation Analysis]
31 Yuan M, Lin L, Cao H, Zheng W, Wu L, Zuo H, Tian X, Song H. Intestinal Microbiota Participates in the Protective Effect of HO-1/BMMSCs on Liver Transplantation With Steatotic Liver Grafts in Rats. Front Microbiol 2022;13:905567. [PMID: 35756057 DOI: 10.3389/fmicb.2022.905567] [Reference Citation Analysis]
32 Sookoian S, Pirola CJ. Precision medicine in nonalcoholic fatty liver disease: New therapeutic insights from genetics and systems biology. Clin Mol Hepatol. 2020;26:461-475. [PMID: 32906228 DOI: 10.3350/cmh.2020.0136] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
33 Pirola CJ, Sookoian S. The lipidome in nonalcoholic fatty liver disease: actionable targets. J Lipid Res 2021;62:100073. [PMID: 33845089 DOI: 10.1016/j.jlr.2021.100073] [Reference Citation Analysis]
34 Sookoian S, Pirola CJ. Liver tissue microbiota in nonalcoholic liver disease: a change in the paradigm of host-bacterial interactions. Hepatobiliary Surg Nutr 2021;10:337-49. [PMID: 34159161 DOI: 10.21037/hbsn-20-270] [Reference Citation Analysis]
35 Pirola CJ, Sookoian S. Epigenetics factors in nonalcoholic fatty liver disease. Expert Review of Gastroenterology & Hepatology. [DOI: 10.1080/17474124.2020.1765772] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
36 Acharya C, Bajaj JS. Chronic Liver Diseases and the Microbiome-Translating Our Knowledge of Gut Microbiota to Management of Chronic Liver Disease. Gastroenterology 2021;160:556-72. [PMID: 33253686 DOI: 10.1053/j.gastro.2020.10.056] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
37 Lamadrid P, Alonso-Peña M, San Segundo D, Arias-Loste M, Crespo J, Lopez-Hoyos M. Innate and Adaptive Immunity Alterations in Metabolic Associated Fatty Liver Disease and Its Implication in COVID-19 Severity. Front Immunol 2021;12:651728. [PMID: 33859644 DOI: 10.3389/fimmu.2021.651728] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
38 Pan Y, Zhang X. Diet and gut microbiome in fatty liver and its associated liver cancer. J Gastroenterol Hepatol 2021. [PMID: 34664301 DOI: 10.1111/jgh.15713] [Reference Citation Analysis]
39 Fang Q, Li X, Wang M, Qiao X, Huang F, Hu C, Xue Y, Zhao S, Lin Y. Walnut green husk ethanol extract improves gut microbiota and their metabolites associated with NLRP3 in non-alcoholic steatohepatitis. Food Funct 2022;13:6387-403. [PMID: 35616069 DOI: 10.1039/d2fo00012a] [Reference Citation Analysis]
40 Xu X, Sun S, Liang L, Lou C, He Q, Ran M, Zhang L, Zhang J, Yan C, Yuan H, Zhou L, Chen X, Dai X, Wang B, Zhang J, Zhao J. Role of the Aryl Hydrocarbon Receptor and Gut Microbiota-Derived Metabolites Indole-3-Acetic Acid in Sulforaphane Alleviates Hepatic Steatosis in Mice. Front Nutr 2021;8:756565. [PMID: 34722615 DOI: 10.3389/fnut.2021.756565] [Reference Citation Analysis]
41 Pafili K, Roden M. Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans. Mol Metab 2021;50:101122. [PMID: 33220492 DOI: 10.1016/j.molmet.2020.101122] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
42 Li Y, Lu X, Li X, Guo X, Sheng Y, Li Y, Xu G, Han X, An L, Du P. Effects of Agaricus blazei Murrill polysaccharides on hyperlipidemic rats by regulation of intestinal microflora. Food Sci Nutr 2020;8:2758-72. [PMID: 32566193 DOI: 10.1002/fsn3.1568] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
43 Wang R, Tang R, Li B, Ma X, Schnabl B, Tilg H. Gut microbiome, liver immunology, and liver diseases.Cell Mol Immunol. 2021;18:4-17. [PMID: 33318628 DOI: 10.1038/s41423-020-00592-6] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 8.0] [Reference Citation Analysis]
44 Wu J, Liu M, Zhou M, Wu L, Yang H, Huang L, Chen C. Isolation and genomic characterization of five novel strains of Erysipelotrichaceae from commercial pigs. BMC Microbiol 2021;21:125. [PMID: 33888068 DOI: 10.1186/s12866-021-02193-3] [Reference Citation Analysis]
45 Pomié C, Servant F, Garidou L, Azalbert V, Waget A, Klopp P, Garret C, Charpentier J, Briand F, Sulpice T, Lelouvier B, Douin-Echinard V, Burcelin R. CX3CR1 regulates gut microbiota and metabolism. A risk factor of type 2 diabetes. Acta Diabetol 2021;58:1035-49. [PMID: 33754166 DOI: 10.1007/s00592-021-01682-1] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
46 Wang Y, Liu Y. Gut-liver-axis: Barrier function of liver sinusoidal endothelial cell. J Gastroenterol Hepatol 2021. [PMID: 33811372 DOI: 10.1111/jgh.15512] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
47 Zhong M, Yan Y, Yuan H, A R, Xu G, Cai F, Yang Y, Wang Y, Zhang W. Astragalus mongholicus polysaccharides ameliorate hepatic lipid accumulation and inflammation as well as modulate gut microbiota in NAFLD rats. Food Funct 2022. [PMID: 35726797 DOI: 10.1039/d2fo01009g] [Reference Citation Analysis]
48 Khan S, Luck H, Winer S, Winer DA. Emerging concepts in intestinal immune control of obesity-related metabolic disease. Nat Commun 2021;12:2598. [PMID: 33972511 DOI: 10.1038/s41467-021-22727-7] [Reference Citation Analysis]
49 Li L, Cheng L, Li Z, Li C, Hong Y, Gu Z. Butyrylated starch protects mice from DSS-induced colitis: combined effects of butyrate release and prebiotic supply. Food Funct 2021;12:11290-302. [PMID: 34635904 DOI: 10.1039/d1fo01913a] [Reference Citation Analysis]
50 Guo L, Yang K, Zhou P, Yong W. Gut microbiota in obesity and nonalcoholic fatty liver disease. Surgery in Practice and Science 2021;5:100030. [DOI: 10.1016/j.sipas.2021.100030] [Reference Citation Analysis]
51 Targher G, Byrne CD, Tilg H. NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications. Gut 2020;69:1691-705. [PMID: 32321858 DOI: 10.1136/gutjnl-2020-320622] [Cited by in Crossref: 130] [Cited by in F6Publishing: 96] [Article Influence: 65.0] [Reference Citation Analysis]
52 Ye G, Zhang X, Yan C, Lin Y, Huang Q. Polystyrene microplastics induce microbial dysbiosis and dysfunction in surrounding seawater. Environ Int 2021;156:106724. [PMID: 34161907 DOI: 10.1016/j.envint.2021.106724] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
53 Simon TG, Roelstraete B, Hagström H, Sundström J, Ludvigsson JF. Non-alcoholic fatty liver disease and incident major adverse cardiovascular events: results from a nationwide histology cohort. Gut 2021:gutjnl-2021-325724. [PMID: 34489307 DOI: 10.1136/gutjnl-2021-325724] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]